Lack of association of CASC8 rs1447295 with colorectal cancer in Iranian population: A multicenter case-control study

Yang

et al. 2020

Front. Cell Dev. Biol.

Section: Discussionmentioning

confidence: 99%

High Cancer Susceptibility Candidate 8 Expression Is Associated With Poor Prognosis of Pancreatic Adenocarcinoma: Validated Analysis Based on Four Cancer Databases

Yang

et al. 2020

Front. Cell Dev. Biol.

“…In our research, 8 m5C-related lncRNAs were carefully chosen via a bioinformatic method, 7 of which have never been previously studied in PDAC (AC022098.1, AL031775.1, AC005332.6, AC096733.3, AC025165.1, AC009974.1, and PAN3-AS1). Only the CASC8 has been reported in the multiple malignant tumor such as colorectal cancer, lung cancer, and hepatocellular carcinoma (37)(38)(39). We checked the above lncRNA expression in the human pancreatic ductal cell line and three pancreatic cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma

et al. 2021

RNA methylation modification is a key process in epigenetics that regulates posttranscriptional gene expression. With advances in next-generation sequencing technology, 5-methylcytosine (m5C) modification has also been found in multiple RNAs. Long non-coding RNAs (lncRNAs) were proved to have a key role in cancer progression and closely related to the tumor immune microenvironment. Thus, based on the PDAC patients’ clinical information and genetic transcriptome data from the TCGA database, we performed a detailed bioinformatic analysis to establish a m5C-related lncRNA prognostic risk model for PDAC patients and discovered the relationship between the risk model and PDAC immune microenvironment. Pearson correlation coefficient analysis was applied to conduct a m5C regulatory gene and m5C-related lncRNA co-expression network. Expression of m5C-related lncRNAs screened by univariate regression analysis with prognostic value showed a significant difference between pancreatic cancer and normal tissues. The least absolute shrinkage and selection operator (LASSO) Cox regression method was applied to determine an 8-m5C-related lncRNA prognostic risk model. We used principal component analysis to indicate that the risk model could distinguish all the samples clearly. The clinical nomogram also accurately predicted 1-, 1.5-, 2-, and 3-year survival time among PDAC patients. Additionally, this risk model was validated in the entire group and sub-test groups using KM analysis and ROC analysis. Combined with the clinical characteristics, the risk score was found to be an independent factor for predicting the survival of PDAC patients. Furthermore, the association between the risk model and tumor immune microenvironment was evaluated via the ESTIMATE R package and CIBERSORT method. Consequently, the results indicated that immune cells were associated with m5C-related lncRNA risk model scores and had different distribution in the high- and low-risk groups. Based on all these analyses, the m5C-related lncRNA risk model could be a reliable prognostic tool and therapeutic target for PDAC patients.

“…The Cancer Susceptibility Candidate 8 (CASC8), which located at 8q24.21, showed significantly copy number amplification. The single-nucleotide polymorphisms of CASC8 have been found to be associated with the risk of EC 15 , hepatocellular carcinoma 16 and colorectal cancer 17 . Moreover, CASC8 exhibited oncogenic role in promoting cell proliferation in bladder cancer 18 and retinoblastoma 19 .…”

Section: Introductionmentioning

confidence: 99%

The m6A-induced lncRNA CASC8 promotes proliferation and chemoresistance via upregulation of hnRNPL in esophageal squamous cell carcinoma

Wu¹,

Zhang²,

Yang³

et al. 2022

Int. J. Biol. Sci.

Long noncoding RNAs (lncRNAs) are dysregulated in many cancers. Here, we identified the molecular mechanisms of lncRNA Cancer Susceptibility Candidate 8 (CASC8) in promoting the malignancy of esophageal squamous cell carcinoma (ESCC). CASC8 was highly overexpressed in ESCC tissues and upregulation of CASC8 predicted poor prognosis in ESCC patients. Moreover, CASC8 decreased the cisplatin sensitivity of ESCC cells and promoted ESCC tumor growth in vivo. Mechanistically, CASC8 interacted with heterogeneous nuclear ribonucleoprotein L (hnRNPL) and inhibited its polyubiquitination and proteasomal degradation, thus stabilizing hnRNPL protein levels and activating the Bcl2/caspase3 pathway. Additionally, AlkB Homolog 5, RNA demethylase (ALKBH5)-mediated m6A demethylation stabilized the CASC8 transcript, resulting in CASC8 upregulation. Taken together, these findings identified an oncogenic function of CASC8 in the progression of ESCC, which suggest that CASC8 might become a potential prognostic biomarker in ESCC.